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FOR THE DCCT/EDIC RESEARCH GROUP*
OBJECTIVE — Althoughdiabetesisknowntoresultinlowerurinarytractsymptoms(LUTS)
in men, it remains unclear if glycemic control can mitigate urinary symptoms. We studied
how diabetic characteristics are related to LUTS in the men who completed the urological
assessment component (UroEDIC) of the Epidemiology of Diabetes Interventions and Com-
plications (EDIC) follow-up study of the Diabetes Control and Complications Trial (DCCT)
participants.
RESEARCH DESIGN AND METHODS — Study participants were men who com-
pleted the UroEDIC questionnaire at the year 10 DCCT/EDIC follow-up examination, which
includeddataongenitourinarytractfunctionandtheAmericanUrologicalAssociationSymptom
Index (AUASI). Analyses were conducted to assess how treatment arm and diabetes character-
istics were associated with LUTS using logistic regression.
RESULTS — Of the 591 men who completed the AUASI questions, nearly 20% (n  115)
had AUASI scores in the moderate to severe category for LUTS (AUASI score 8). No
associations were observed between LUTS and treatment arm, or A1C levels at the DCCT
baseline or end-of-study or at the year 10 EDIC (UroEDIC) examination. Of the diabetes
complicationsstudied,onlyerectiledysfunctionattheUroEDICexaminationwasassociated
with LUTS.
CONCLUSIONS — These data from the UroEDIC cohort do not support the assumption
that intensive glycemic control results in decreased lower urinary tract symptom severity in men
with type 1 diabetes. This result may be due to a true lack of effect, or it may be due to other
factors, for example, the relatively young age of the cohort.
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D
iabetes and urologic diseases are
very common health problems that
markedly increase in prevalence
andincidencewithadvancingage(1).Di-
abetes,whichhasbeenassociatedwithan
earlier onset and increased severity of
urologic diseases, often results in costly
and debilitating urologic complications.
These urologic complications include
bladder dysfunction and have a profound
effect on the quality of life for men with
diabetes. Speciﬁcally, over 50% of men
with diabetes experience some kind of
bladder dysfunction (2). In its most se-
vere form, this dysfunction termed “blad-
der cystopathy” has been classically
described as diminished bladder sensa-
tion, poor contractility, and increased
postvoid residual urine (3). However,
currentunderstandingofdiabeticbladder
dysfunction reﬂects a progressive condi-
tion encompassing a broad spectrum of
bladderdisordersincludinglowerurinary
tract symptoms (LUTS) of urgency, fre-
quency, nocturia, and incontinence.
LUTS are the most common manifesta-
tion of diabetic bladder dysfunction,
whereas bladder cystopathy is relatively
uncommon and most likely represents
end-stage bladder failure with symptoms
of infrequent voiding, difﬁculty initiating
voiding, and postvoid fullness.
The Diabetes Control and Complica-
tions Trial (DCCT) and its long-term ob-
servational follow-up, the Epidemiology
of Diabetes Interventions and Complica-
tions (EDIC) study, have demonstrated
that intensive diabetes therapy reduces
the development and progression of
many diabetes complications, including
retinopathy, nephropathy and peripheral
neuropathy (4). Furthermore, observa-
tional studies have found that markers of
more severe diabetes, including poor lev-
els of glycemic control, are associated
with an increased risk of LUTS (5). How-
ever, in many of these studies, LUTS was
deﬁned as including diagnoses or mark-
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were limited by the inclusion of a rela-
tively small sample of diabetic men. In
addition,mostofthemenwithdiabetesin
thesestudieshadorwerepresumedtohave
type 2 diabetes. To the best of our knowl-
edge, no data from randomized trials exist
to substantiate whether intensive glycemic
control can in fact reduce the risk of subse-
quent adverse lower urinary tract symp-
toms in men with type 1 diabetes.
We examined if glycemic control and
other clinical diabetes-related factors af-
fect the risk of LUTS among the men who
participated in the UroEDIC portion of
the DCCT/EDIC study. The DCCT was a
randomized controlled clinical trial de-
signed to identify the impact of glycemic
control on the development and/or pro-
gression of microvascular complications;
the EDIC study is the long-term epidemi-




The inclusion and exclusion criteria for
the DCCT and the treatment protocol
have been described in detail previously
(6). Brieﬂy, 1,441 subjects between 13
and 39 years of age (53% male) with type
1 diabetes were recruited between 1983
and 1989 to participate in the DCCT in
two cohorts. The primary prevention co-
hortconsistedof726subjectswithnoret-
inopathy, a urinary albumin excretion
rate (AER) 40 mg/24 h, and diabetes
durationof1–5yearsatbaseline.Thesec-
ondary intervention cohort consisted of
715 subjects who had nonproliferative
retinopathy, urinary AER 200 mg/24 h,
and diabetes duration of 1–15 years. In-
dividuals were excluded if they had hy-
pertension (deﬁned by systolic 140 or
diastolic 90 mmHg), a history of
symptomatic ischemic heart disease, or
the presence of symptomatic peripheral
neuropathy.
The 1,441 subjects were randomized
toreceiveeitherintensiveorconventional
diabetes therapy. Intensive treatment
consisted of insulin administered three or
moretimesperdaybyinjectionorbycon-
tinuous subcutaneous infusion with an
external pump. Frequent daily self-
monitoring of capillary glucose levels was
performed, and the results, coupled with
anticipated meal content and exercise,
were used to adjust insulin doses. Treat-
ment goals were preprandial blood glu-
cose levels between 70 and120 mg/dl
(3.89 and 6.66 mmol/l), postprandial
blood glucose levels 180 mg/dl (9.99
mmol/l), a weekly 0300 h measurement
65 mg/dl (3.61 mmol/l), a monthly
measured A1C level within the nondia-
betic range (6.05%), and avoidance of
severe hypoglycemia. Conventional ther-
apy consisted of one or two daily insulin
injections; the treatment goal was free-
dom from symptoms of hyperglycemia
and frequent or severe hyperglycemia.
Theintensiveandconventionaltreatment
groupsmaintainedaseparationofmedian
A1C level of about two percentage points
throughout the DCCT (7.1% compared
with 9.0%; P  0.001). The DCCT was
terminated in 1993 when the principal
study question concerning treatment ef-
fects had been answered; the mean dura-
tion of follow-up in the DCCT was 6.5
years. At the end of the DCCT, partici-
pants were referred to their own health
care provider for ongoing care. In 1994,
1,394 (96%) of DCCT subjects, 687 from
the intensive arm and 688 from the con-
ventionalarm,agreedtoparticipateinthe
EDIC follow-up study, which included
annual examinations for complication
status (7).
UroEDIC participation
All men enrolled in EDIC at year 10 (n 
713) were invited to participate in the
UroEDIC Study, an ancillary study to ex-
amine the presence of urological compli-
cations, including lower urinary tract
symptoms and erectile dysfunction. Of
these,591(83%)consentedtoparticipate
in UroEDIC and completed the questions
regarding LUTS, as noted below. The in-
stitutional review board of each partici-
pating center approved the study, and a
certiﬁcateofconﬁdentialitywasissuedfor
this study by the federal government.
Assessment of lower urinary tract
symptoms
Lowerurinarytractsymptomseveritywas
assessed at the year 10 annual examina-
tion with the American Urological Asso-
ciation Symptom Index (AUASI) (8). The
AUASI is a standardized seven-itemques-
tionnaire that quantiﬁes the presence and
frequency of the following lower urinary
tract symptoms: nocturia, frequency, ur-
gency, weak urinary stream, intermit-
tency, straining, and the sensation of
incompleteemptying.Scoresontheindex
range from 0 to 35, with widely accepted
cut points of 0–7, 8–19, and 20–35 des-
ignated as none/mild, moderate, and se-
vereLUTS,respectively(9).Becausethere
were relatively few men with AUASI
scores above 20 in the EDIC study, men
with AUASI scores 8 were considered
together in a category of moderate/severe
LUTS.
The seven lower urinary tract symp-
toms assessed in the AUASI were addi-
tionally categorized as irritative (or
storage)orvoiding(orobstructive)symp-
toms. Irritative symptoms included fre-
quency, urgency, and nocturia, while
obstructivesymptomsincludedweakuri-
nary stream, intermittency, straining, and
the sensation of incomplete emptying.
Diabetes measurements
A1C was measured at baseline and quar-
terly during DCCT and annually in EDIC
as previously described. For purposes of
this analysis, we used A1C levels mea-
sured at baseline, the end of the DCCT,
and at year 10 in EDIC (concurrent with
the UroEDIC assessment) (10).
Diabetes complications
Peripheral neuropathy status in the
DCCTwasdeﬁnedbythepresenceofdef-
inite clinically evident distal symmetrical
polyneuropathy and an abnormal nerve
conduction study or based on responses
to the Michigan Neuropathy Screening
Instrument during EDIC (11). Neuropa-
thy was deﬁned to be present with more
than six positive responses on the Michi-
gan Neuropathy Screening Instrument
questionnaire or a score 2 on the exam-
ination—thresholds deﬁned by prior val-
idation studies (11,12). Retinopathy was
assessed annually in the EDIC in one-
quarter of the cohort and in all partici-
pants at EDIC years 4 and 10 using
stereoscopic fundus photographs that
were centrally graded using the Early
Treatment Diabetic Retinopathy Study
(ETDRS)(13)scaleof0–23(1–11non-
proliferative, 12  proliferative). Albu-
minexcretionrate(AER)wasmeasuredin
half the cohort annually. Nephropathy
was deﬁned as microalbuminuria if AER
was 40–299 mg/24 h or albuminuria if
AER was 300 mg/24 h. The extent of
atherosclerosis was assessed by measure-
ment of intima-media thickness of the in-
ternal and common carotid arteries from
centrally graded carotid ultrasonography
(14) at EDIC year 1 and 6 and by mea-
surement of the percentage of coronary
artery calciﬁcation present on centrally
graded computed cardiac tomography
conducted during EDIC years 6–7 (15).
Erectile dysfunction was deﬁned in a bi-
nary fashion based on responses to the
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would you rate your conﬁdence that you
get and keep your erection?” If the partic-
ipant answered “very low” (1) or “low”
(2), he was considered to have erectile
dysfunction, while men who answered
“moderate” (3), “high” (4), or “very high”
(5) were considered to have no erectile
dysfunction.
Statistical analysis
To test for differences between groups,
the Wilcoxon’s rank-sum test was used
for quantitative variables, and the contin-
gency
2testwasusedforqualitativevari-
ables. The Fisher’s exact test was used
where appropriate. All analyses were per-
formed using SAS version 8.2 (SAS Insti-
tute, Cary, NC).
Logistic regression analysis was used
to estimate the odds of moderate/severe
LUTS associated with glycemic control
and other diabetes complications. Statis-
tical tests of the regression estimates were
based on the 
2 approximation for the
likelihood ratio statistic, and 95% CIs
were based on the Wald’s test.
Univariate logistic regression models
were ﬁt without adjustment. Multivariate
models were ﬁt adjusting for the follow-
ing a priori variables from Table 2: age,
BMI, race, use of an -blocking agent,
smoking status, drinking status, level of
education, martial status, and exercise
status. Models also assessed interactions
among these factors within diabetes treat-
ment group.
RESULTS— Of the 713 men who par-
ticipated in the year 10 EDIC examina-
tion, 591 (82.8%) completed the AUASI
component of the UroEDIC question-
naire. No signiﬁcant differences were
noted at baseline between men who com-
pletedthesymptomindexcomparedwith
those who did not, with the exception
that the UroEDIC participants had lower
total cholesterol levels at DCCT baseline
(179.1 vs. 171.5 mg/dl, P  0.022) and
lower mean blood pressure at EDIC year
10 (94.4 vs. 92.3 mmHg, P  0.025) rel-
ative to nonparticipants.
The men who participated in the an-
cillary UroEDIC study were on average
44.66.6yearsofage(meansSD)and
had a mean A1C level at EDIC year 10 of
7.72  1.3%. Table 1 presents socioeco-
nomic and diabetic characteristics at
DCCT baseline and at the year 10
UroEDIC examination by DCCT treat-
ment assignment. At DCCT baseline,
there were no signiﬁcant differences be-
tween the treatment groups, demonstrat-
ing that the randomization process
worked. However, of the men participat-
ing at the year 10 examination in EDIC,
those randomized to intensive treatment
were signiﬁcantly more likely to have
longer diabetes duration, use higher
Table 1—Clinical characteristics of the male UroEDIC cohort
DCCT baseline (1983–1989) Year 10 EDIC (2003)
Conventional Intensive P Conventional Intensive P
n 302 289 302 289
Sociodemographic characteristics
Age (years) 27.6  6.7 27.4  6.8 0.90 44.6  6.6 44.7  6.6 0.89
Race*
White, not of Hispanic origin 293 (97.0) 277 (95.8) 293 (97.0) 277 (95.8)
Black, not of Hispanic origin 4 (1.3) 7 (2.4) 0.48 4 (1.3) 7 (2.4) 0.48
Hispanic 4 (1.3) 2 (0.7) 4 (1.3) 2 (0.7)
Asian or Paciﬁc Islander 1 (0.3) 3 (1.0) 1 (0.3) 3 (1.0)
Married 169 (56.0) 146 (50.5) 0.19 223 (75.9) 221 (78.4) 0.47
Cigarette smoker† 53 (17.5) 58 (20.1) 0.43 98 (33.0) 99 (34.7) 0.66
Diabetes treatment and control
Cohort
Primary number 159 (52.6) 138 (47.8) 0.23 — — 0.23
Secondary number 143 (47.4) 151 (52.2) — —
Diabetes duration (years) 5.1  3.9 5.7  4.1 0.06 21.7  4.6 22.6  4.9 0.04
A1C 8.9  1.5 8.9  1.5 0.59 7.7  1.3 7.8  1.2 0.13
Insulin dose (units   kg
1   day
1) 0.63  0.24 0.67  0.25 0.08 0.68  0.23 0.73  0.27 0.03
Microvascular complications
Retinopathy‡
Nonproliferative or none 302 (100.0) 289 (100.0) 0.62 143 (47.4) 208 (72.0) 0.001
Proliferative 0 (0.0) 0 (0.0) 159 (52.6) 81 (28.0)
Nephropathy
None (AER§ 40) 289 (95.7) 274 (94.8) 205 (67.9) 219 (75.8)
Microalbuminuria (40  AER  300) 13 (4.3) 15 (5.2) 0.61 48 (15.9) 58 (20.1) 0.001
Albuminuria (AER 300) 0 (0.0) 0 (0.0) 49 (16.2) 12 (4.2)
Hypertension¶ 0 (0.0) 0 (0.0) — 155 (52.2) 113 (39.6) 0.002
Creatinine clearance (ml/min per 1.73 m
2) 132.2 (26.0) 133.1 (31.3) 0.87 117.5 (28.9) 122.5 (28.9) 0.03
Peripheral neuropathy# 20 (6.6) 23 (8.0) 0.53 227 (75.2) 189 (65.4) 0.009
Data are means  SD or n (%). *Race was classiﬁed by the participant during the enrollment interview in the DCCT. †Deﬁned as having ever smoked. ‡Determined
by the Early Treatment Diabetic Retinopathy Study on a scale of 0–23; 12 nonproliferative, 12 proliferative. §Albumin excretion rate (mg/24 h). ¶Hypertension
is deﬁned as sitting systolic blood pressure 140 mmHg and/or diastolic blood pressure 90 mmHg or the use of antihypertensive medication. #Deﬁned in the
DCCTbythepresenceofdeﬁniteclinicallyevidentdistalsymmetricalpolyneuropathyandanabnormalnerveconductionstudy,orinEDICbymorethansixpositive
responses on the Michigan Neuropathy Screening Instrument questionnaire or a score 2 on the examination.
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Moderate/severe LUTS No/mild LUTS P
n 115 476
Sociodemographic characteristics
Age (years) 46.6  6.4 44.1  6.6 0.001
Race
White, not of Hispanic origin 111 (96.5) 459 (96.4)
Black, not of Hispanic origin 2 (1.7) 9 (1.9) 0.68
Hispanic 2 (1.7) 4 (0.8)
Asian or Paciﬁc Islander 0 (0.0) 4 (0.8)
Married 83 (74.1) 361 (77.8) 0.40
Graduate education 26 (23.0) 107 (23.0) 0.99
Cigarette smoker 40 (35.4) 157 (33.5) 0.70
Drinking status 63 (55.8) 234 (50.2) 0.29
BMI (kg/m
2) 27.5 (3.9) 28.1 (4.2) 0.29
Sildenaﬁl citrate use* 8 (7.0) 22 (4.6) 0.31
-Blocker use 3 (2.8) 1 (0.2) 0.03
Diabetes treatment and control
Diabetes duration (years) 22.0  4.9 22.2  4.7 0.53
Arm of DCCT
Intensive 60 (52) 229 (48) 0.51
Conventional 55 (48) 247 (52)
Cohort
Primary 61 (53.0) 236 (49.6) 0.51
Secondary 54 (47.0) 240 (50.4)
A1C at DCCT baseline (%) 8.8  1.4 8.7  1.5 0.38
DCCT mean A1C 8.1  1.3 8.1  1.4 0.80
Time weighted DCCT/EDIC mean A1C 8.1  1.0 8.1  1.1 0.84
Insulin dose (units   kg
1   day
1) 0.7  0.2 0.7  0.3 0.56
Microvascular complications
Retinopathy†
Nonproliferative or none 64 (55.7) 287 (60.3) 0.36
Proliferative 51 (44.3) 189 (39.7)
Nephropathy
None (AER‡ 40) 77 (67.0) 347 (72.9)
Microalbuminuria (40  AER  300) 22 (19.1) 84 (17.6) 0.31
Albuminuria (AER 300) 16 (13.9) 45 (9.5)
Creatinine clearance (ml/min per 1.73 m
2) 117.5  32.0 120.6  28.2 0.26
Hypertension§ 51 (45.1) 217 (46.3) 0.83
Peripheral neuropathy ever during DCCT and EDIC¶ 92 (80.0) 324 (68.1) 0.01
Macrovascular complications
Coronary calciﬁcation at EDIC year 10 0 50 (48.1) 170 (38.6) 0.08
Carotid intimal medial thickness at EDIC year 1# 0.7  1.7 0.2  1.7 0.002
Carotid intimal medial thickness at EDIC year 6# 0.6  1.7 0.3  1.8 0.05
Total cholesterol (mg/dl) 181.6  34.8 179.1  33.3 0.61
Triglyceride (mg/dl) 102.3  68.8 96.2  65.0 0.53
Other complications
Erectile dysfunction** 44 (39.3) 88 (19.2) 0.001
Occlusion (ABI†† 0.9) 9  7.8 38  8.0 0.96
Clinically signiﬁcant occlusion (ABI 0.8) 3  2.6 15  3.2 0.99
Calciﬁcation (ABI 1.3) 4  3.5 22  4.6 0.59
Data are means  SD or n (%). All variables are at EDIC year 10 except where indicated. *Sildenaﬁl citrate use reported during yearly EDIC drug inventory.
†Determined by ETDRS 12 nonproliferative, 12 proliferative. ‡Albumin excretion rate (mg/24 h). §Hypertension is deﬁned as sitting systolic blood pressure
140 mmHg and/or diastolic blood pressure 90 mmHg or the use of antihypertensive medication. ¶Deﬁned in the DCCT by the presence of deﬁnite clinically
evident distal symmetrical polyneuropathy and an abnormal nerve conduction study or in EDIC by more than six positive responses on the Michigan Neuropathy
Screening Instrument questionnaire or a score 2 on the examination. #Combined intimal medial thickness. **Erectile dysfunction was assessed in UroEDIC with
an anonymous questionnaire that included the erectile function, orgasmic, and desire domains of the International Index of Erectile Function (IIEF). A binary
outcome variable for erectile dysfunction was created based on responses to the question: “Over the past 4 weeks, how would you rate your conﬁdence that you get
and keep your erection?” If the participant answered “very low” (1) or “low” (2), they were considered to have erectile dysfunction. If they answered “moderate” (3),
“high”(4),or“veryhigh”(5),theywereconsideredtohavenoerectiledysfunction.††Themeanofthetwobrachialpressureswasdividedintoeachofthefoursystolic
ankle pressures to yield four values for the ankle-brachial pressure index (ABI). The ABI selected for the analysis was the smallest of the four ratios.
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inine clearance, but were less likely to
have retinopathy, nephropathy, periph-
eral neuropathy, and erectile dysfunction




characteristics and the presence of LUTS.
Approximately 20% of the men reported
moderateorsevereLUTS.Ofthe115men
with LUTS, only 6 men reported severe
LUTS, with the remainder in the moder-
ate range. Frequency of LUTS increased
with age (Fig. 1). Compared with men
without LUTS, men with LUTS were on
average older, had peripheral neuropathy
either during the DCCT or during EDIC,
had a carotid intimal medial thickness
that was higher at EDIC year 1, and re-
ported erectile dysfunction. No differ-
ences were observed for the other
socioeconomic or diabetes characteristics
by LUTS status. However, the use of
-blockers was greater among men with
LUTS compared with men without LUTS
(2.8 vs. 0.2%, respectively, P  0.03).
Adjusted for DCCT baseline factors,
intensivetherapycomparedwithconven-
tional therapy did not reduce the risk of
having moderate or severe LUTS (odds
ratio [OR] 0.84, 95% CI 0.55–1.28, P 
0.30).
In multivariate analyses adjusted for
othersocioeconomicanddiabetescharac-
teristics at EDIC year 10, only erectile
dysfunction was associated with LUTS
(OR 2.54, 95% CI 1.53–4.20, P 
0.0002). No other diabetic characteristic,
including DCCT treatment group assign-
ment, cohort, or A1C level was associated
with LUTS.
CONCLUSIONS— Among men
with a duration of type 1 diabetes of 20
years initially enrolled in a clinical trial
designed to evaluate the impact of inten-
sive versus conventional therapy on
glycemic control, one in ﬁve reported
moderate to severe LUTS. The prevalence
of LUTS noted in the EDIC study is lower
than estimates from epidemiologic stud-
ies (16,17), most of which were of com-
munity-dwelling men with few cases of
diabetes. Estimates of the prevalence of
LUTSamongmenofcomparableagewith
diabetes in the Flint Men’s Health Study
or Olmsted County Study were 38–
58%; most of these men had type 2 dia-
betes (A.V.S., personal communication).
We had anticipated a higher preva-
lence of LUTS in the DCCT/EDIC cohort
ofmenwithtype1diabetes.Theremaybe
several explanations for the lower ob-
served prevalence in this study. First,
control of glycemia in this population is
undoubtedly better than that in the gen-
eral population of men with type 1 diabe-
tes, possibly contributing to a reduction
in the severity of urinary symptoms. Sec-
ond, the mean age of the men in the
DCCT/EDIC is younger than when most
men are bothered enough by urinary
symptoms to visit a health care provider.
Longer-term follow-up of the EDIC co-
hort may be required to determine if the
prevalence and/or severity increases sub-
stantiallyasthesemenreachtheir50sand
60s. Finally, another factor may be a se-
lection bias of the participants who en-
rolled in the clinical trial; individuals
were excluded from originally enrolling
in the DCCT if they had any sign of ad-
vanced microvascular complications or
other signiﬁcant medical or psychiatric
disorders. Whether men found eligible
and who participated in the DCCT/EDIC
through the year 10 UroEDIC study were
less likely to develop moderate to severe
LUTS over the course of follow-up com-
pared with all type 1 diabetic men cannot
be determined.
When a large number of clinical and
demographic characteristics were consid-
ered, only erectile dysfunction was inde-
pendently associated with LUTS. Several
priorstudies,whichhavemostlyincluded
men without diabetes, have found that
self-reported erectile dysfunction and
LUTS occur together (18). Given the ex-
quisite sensitivity of erectile function to
systemic diabetes perturbations, the asso-
ciation observed here is likely to be a bet-
termarkerofthedegreetowhichdiabetes
has disrupted vascular, endocrine, hor-
monal, and neuropathic function directly
relevant to voiding function than the
otherdiabetescomplicationsthatwerein-
cluded in this study. Examining how dys-
function in these body systems affects
LUTS in future EDIC examinations will
be important to better understanding this
association.
We did not ﬁnd a beneﬁcial effect of
intensive glycemic control on prevalence
ofmoderatetosevereLUTS.A1Clevelsat
the beginning and end of the DCCT or at
the year 10 EDIC examination, when uri-
nary symptoms were assessed, were not
associatedwithLUTS,asmeasuredbythe
AUASI. Because diabetic cystopathy
might be better reﬂected in irritative
symptoms of the AUASI, we also con-
ducted analyses stratiﬁed by irritative or
obstructive grouping. However, we saw
no difference from our primary results in
these analyses.
Whereas there is general agreement
that diabetes results in LUTS (1,19), the
epidemiology of diabetes and LUTS is not
clear. Much of the epidemiology in this
area has been limited because prior stud-
ies that use markers of LUTS (e.g., trans-
urethral resection of the prostate or
TURP) (20) have included few men with
diabetes, and/or included solely or pri-
marily men with type 2 diabetes. None-
theless, the Massachusetts Male Aging
Study (21), Flint Men’s Health Study (9),
and others have consistently reported di-
Figure 1—Prevalence of LUTS by age and treatment group. LUTS is deﬁned as an AUASI 8.
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with an increased risk of LUTS with or
without benign prostatic hyperplasia.
Progression of LUTS has been reported to
be greater in men with diabetes than in
thosewithoutdiabetes,intheabsenceofa
difference in prostate volume growth be-
tween the two groups (22), suggesting a
progressive impact on the bladder. How-
ever, these studies have not examined
how glycemic control affects LUTS.
Whereas a signiﬁcant number of
studies have shown that diabetes affects
the bladder (1), there may be several rea-
sons why this study did not identify an
association between glycemic control and
LUTS. First, there may truly be no effect
of glycemic control on LUTS in this co-
hort of men with type 1 diabetes. Because
they have had type 1 diabetes for a signif-
icant period of time, the opportunity for
glycemic control to inﬂuence LUTS may
have passed. It may be due to the lack of
metabolic memory, where effects of met-
abolic changes in the past (e.g., glycemic
control) continue to exert an effect at a
later time, regardless of current circum-
stances (23). For example, numerous
other complications from diabetes have
been positively affected by the use of in-
tensive therapy and the improvement in
glycemic control during the DCCT
(4,15). It may be that there is no meta-
bolic memory effect of effective glycemic
control on the presence or development
of LUTS. Second, it may also be that there
are conﬂicting impacts of diabetes and
glycemic control on the prostate and
bladder, such that no effect is observed. If
diabetes slows down prostate growth via
itsimpactontestosteroneandgrowthfac-
tors, it might reduce the risk of LUTS (via
obstructive mechanism) and mask bene-
ﬁcial effects of glycemic control on blad-
der dysfunction. Third, as noted above,
these men were relatively younger on av-
erage than the population of males that
typicallyexperienceanincreaseinthefre-
quency of LUTS. Thus, an insufﬁcient
number of men may have been in the pri-
mary risk period for developing LUTS,
and additional follow-up of these men
may reveal a different result regarding the
relationship between glycemic control
and LUTS.
In summary, data from this study do
notsupportanassociationbetweenglyce-
mic control and a decrease in lower uri-
nary tract symptoms. This may be due to
the long period of time these men have
had diabetes where the (beneﬁcial) inﬂu-
ence of glycemic control on bladder dys-
function was past. However, it may also
be that these men were younger on aver-
age than when most men typically mani-
fest LUTS. To assess the impact of
glycemic control on LUTS, it will be im-
portant to reexamine this cohort when
they are of an age when LUTS is more
prevalent.
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